After her weight has been stable for 2–3 months, she has several options to maintain her weight loss, including (1) continue GLP-1s/IMs at the current full dose or (2) alternative strategies that incorporate behavioral interventions and nutritional support, and a lower cost medication regimen—for example, (2a) less intensive GLP-1/IM therapy (eg, every other week instead of weekly) or (2b) transition to a less expensive anti-obesity medication tailored to the individual patient (eg, phentermine/topiramate if using highly effective contraception). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.